廣告
香港股市 已收市

  • 恒指

    18,475.92
    +268.79 (+1.48%)
     

  • 國指

    6,547.29
    +110.20 (+1.71%)
     

  • 上證綜指

    3,104.82
    -8.22 (-0.26%)
     

  • 滬深300

    3,604.39
    -19.52 (-0.54%)
     

  • 美元

    7.8126
    -0.0007 (-0.01%)
     

  • 人民幣

    0.9263
    +0.0002 (+0.02%)
     

  • 道指

    38,664.33
    +438.67 (+1.15%)
     

  • 標普 500

    5,112.84
    +48.64 (+0.96%)
     

  • 納指

    16,115.00
    +274.04 (+1.73%)
     

  • 日圓

    0.0510
    +0.0004 (+0.73%)
     

  • 歐元

    8.4179
    +0.0401 (+0.48%)
     

  • 英鎊

    9.8170
    +0.0250 (+0.26%)
     

  • 紐約期油

    78.73
    -0.22 (-0.28%)
     

  • 金價

    2,311.90
    +2.30 (+0.10%)
     

  • Bitcoin

    61,586.95
    +3,160.66 (+5.41%)
     

  • CMC Crypto 200

    1,316.82
    +39.84 (+3.12%)
     

Why CEL-SCI Shares Are Shooting Higher Today

Vandana Singh
·1 分鐘文章

CEL-SCI Corporation (NYSE: CVM) announced that the latest results from its pivotal Phase 3 study of Multikine, a presurgical cancer immunotherapy, were presented at the European Society for Radiotherapy and Oncology (ESTRO) 2023 Congress.

CEL-SCI's IT-MATTERS Phase 3 study reported a statistically significant 14.1% absolute 5-year overall survival benefit in the intent-to-treat (ITT) subjects who were categorized as a lower risk to recurrence (LR) and received Multikine followed by surgery and radiotherapy, as compared to control LR subjects who received only standard of care (SOC) (surgery plus radiotherapy).

Related: CEL-SCI's Lead Head & Neck Cancer Candidate Shows 43% Survival Extension.

廣告

The histopathology analysis showed an association with improved overall survival, progression-free survival, and local, regional control that significantly favored Multikine-treated [(61/279 or 21.9% >> 2.5% by chance alone) vs. SOC-treated (5/279 (or 1.9% < 2.5% by chance alone)].

Overall survival of 63.9% vs. 44.4%, with Progression Free Survival of 56.9%.

HP LR Multikine-treated subjects had a significantly lower (39.1% [45/115]) death rate versus a 53.7% (51/95) death rate for HP LR SOC alone.

Price Action: CVM shares are up 9.17% at $2.62 on the last check Monday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Why CEL-SCI Shares Are Shooting Higher Today originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.